iRhythm Holdings announces a $100 million accelerated share repurchase agreement with JPMorgan as part of a $200 million program.
Quiver AI Summary
iRhythm Holdings, Inc. announced that it has entered into a $100 million accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank as part of a larger $200 million share repurchase authorization. iRhythm will pay JPMorgan $100 million initially and will receive around 80% of the total shares anticipated to be repurchased under the ASR. The final number of shares bought will depend on the stock's average price throughout the ASR period, with settlement expected by the first quarter of 2027. Following this ASR, the company will have about $100 million remaining in its repurchase authorization, which it plans to fund using existing cash reserves. iRhythm focuses on developing digital health solutions that leverage biosensors and data analytics to enhance patient care.
Potential Positives
- iRhythm has initiated a $100 million accelerated share repurchase (ASR) agreement, indicating confidence in its financial position and commitment to shareholder value.
- The ASR allows iRhythm to repurchase approximately 80% of the expected shares immediately, which can provide a positive signal to the market regarding the company's stock valuation.
- Following the completion of this ASR, iRhythm will have $100 million remaining for additional share repurchases, suggesting continued commitment to returning capital to shareholders.
- The funding for the ASR will come from existing cash and cash equivalents, indicating strong liquidity and financial health.
Potential Negatives
- The announcement of the $100 million accelerated share repurchase (ASR) may signal that the company lacks better investment opportunities, which could be interpreted negatively by investors.
- The reliance on existing cash and cash equivalents to fund the ASR raises concerns about liquidity and financial flexibility, especially with only $100 million remaining under the repurchase authorization.
- The press release includes numerous forward-looking statements about the ASR, indicating inherent risks and uncertainties that may affect the company's future performance and execution of the repurchase plan.
FAQ
What is the recent announcement by iRhythm Holdings?
iRhythm Holdings announced an accelerated share repurchase agreement with JPMorgan for $100 million of its common stock.
How much does iRhythm plan to spend on share repurchases?
The company has a total share repurchase authorization of $200 million, with an initial $100 million committed in this ASR.
Who is handling the share repurchase agreement?
JPMorgan Chase Bank is managing the accelerated share repurchase agreement for iRhythm Holdings.
When is the final settlement of the ASR expected?
The final settlement of the accelerated share repurchase is expected to occur by the first quarter of 2027.
How will iRhythm fund the share repurchase program?
iRhythm expects to fund the repurchase program with its existing cash and cash equivalents.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IRTC Insider Trading Activity
$IRTC insiders have traded $IRTC stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $IRTC stock by insiders over the last 6 months:
- QUENTIN S. BLACKFORD (President and CEO) sold 26,859 shares for an estimated $3,348,011
- MINANG TURAKHIA (CHIEF MED/SCI OFCR EVP ADVTECH) has made 0 purchases and 2 sales selling 8,516 shares for an estimated $1,061,613.
- CHAD PATTERSON (CHIEF COMM & PRODUCT OFFICER) sold 7,093 shares for an estimated $884,170
- PATRICK MICHAEL MURPHY (CBO and CLO) sold 7,093 shares for an estimated $884,155
- SUMI SHRISHRIMAL (EVP, Chief Risk Officer) sold 5,372 shares for an estimated $669,640
- SEAN CLINTON FREEMAN (EVP, Strategy & Corp Devt) sold 918 shares for an estimated $114,483
- DANIEL G. WILSON (Chief Financial Officer) sold 773 shares for an estimated $94,174
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IRTC Revenue
$IRTC had revenues of $221.6M in Q3 2026. This is an increase of 14.88% from the same period in the prior year.
You can track IRTC financials on Quiver Quantitative's IRTC stock page.
You can access data on IRTC stock through the Quiver Quantitative API.
$IRTC Hedge Fund Activity
We have seen 191 institutional investors add shares of $IRTC stock to their portfolio, and 164 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 5,203,443 shares (-99.3%) from their portfolio in Q3 2026, for an estimated $591,423,331
- SANDS CAPITAL MANAGEMENT, LLC removed 1,699,645 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $202,172,772
- MILLENNIUM MANAGEMENT LLC removed 1,057,367 shares (-75.2%) from their portfolio in Q3 2026, for an estimated $120,180,333
- RTW INVESTMENTS, LP added 936,282 shares (+42.9%) to their portfolio in Q3 2026, for an estimated $106,417,812
- INVESCO LTD. added 774,585 shares (+3497.6%) to their portfolio in Q3 2026, for an estimated $88,039,331
- JPMORGAN CHASE & CO removed 705,893 shares (-92.1%) from their portfolio in Q3 2026, for an estimated $80,231,798
- HOLOCENE ADVISORS, LP removed 553,751 shares (-70.7%) from their portfolio in Q3 2026, for an estimated $62,939,338
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$IRTC Analyst Ratings
Wall Street analysts have issued reports on $IRTC in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 11/11/2026
- Truist Securities issued a "Buy" rating on 11/09/2026
- Freedom Capital Markets issued a "Buy" rating on 11/09/2026
- JP Morgan issued a "Overweight" rating on 11/06/2026
- Canaccord Genuity issued a "Buy" rating on 11/06/2026
- Wells Fargo issued a "Overweight" rating on 11/06/2026
- Evercore ISI Group issued a "Outperform" rating on 11/06/2026
To track analyst ratings and price targets for $IRTC, check out Quiver Quantitative's $IRTC forecast page.
$IRTC Price Targets
Multiple analysts have issued price targets for $IRTC recently. We have seen 11 analysts offer price targets for $IRTC in the last 6 months, with a median target of $145.0.
Here are some recent targets:
- Mason Carrico from Stephens & Co. set a target price of $120.0 on 11/11/2026
- Richard Newitter from Truist Securities set a target price of $140.0 on 11/09/2026
- Gene Mannheimer from Freedom Capital Markets set a target price of $159.0 on 11/09/2026
- Allen Gong from JP Morgan set a target price of $145.0 on 11/06/2026
- Joanne Wuensch from Citigroup set a target price of $124.0 on 11/06/2026
- William Plovanic from Canaccord Genuity set a target price of $206.0 on 11/06/2026
- Nathan Treybeck from Wells Fargo set a target price of $135.0 on 11/06/2026
Full Release
SAN FRANCISCO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association (JPMorgan) for $100 million of its common stock, as part of its previously announced $200 million share repurchase authorization.
Under the terms of the ASR, iRhythm will make an initial payment of $100 million to JPMorgan and receive an initial delivery of shares representing approximately 80% of the total number of shares expected to be repurchased under the ASR. The total number of shares that iRhythm will ultimately repurchase under the ASR will be determined based on the volume-weighted average price of the company's common stock during the term of the ASR, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreement. Final settlement of the ASR is expected to occur no later than the first quarter of 2027. Following completion of the ASR, iRhythm will have approximately $100 million remaining available under its outstanding share repurchase authorization.
The company expects to fund this ASR with existing cash and cash equivalents.
About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For more information, visit www.irhythmtech.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include, without limitation, statements regarding the ASR, including the total number of shares to be repurchased under the ASR and the timing of final settlement of the ASR, and the amount, timing, methods and sources of funding of repurchases under the share repurchase program and the structure of such repurchases. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: risks relating to the fact that the ASR and other common stock repurchases may not be conducted in the timeframe or in the manner we expect, or at all; risks relating to the final number of shares repurchased under the ASR, which will depend on the trading price of our common stock during the term of the ASR; intense competition in the markets we compete in; fluctuations in our operating results; future reimbursement and regulatory conditions; financial market conditions; the execution and effect of our business strategy; future business decisions made by us and our competitors; and additional risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 5, 2026. These forward-looking statements speak only as of the date of this press release and should not be unduly relied upon. We undertake no obligation to update them except as required by law.
Investor Contact
Francis Pruell
Media Contact
Kassandra Perry